Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab + carboplatin-pemetrexed versus carboplatin-pemetrexed in EGFR exon 20 insertion-mutated advanced non-small cell lung cancer
2023-506033-29-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Amivantamab + carboplatin + pemetrexed with Carboplatin + pemetrexed (2 arms). Primary endpoint: Progression-free survival. Planned start Oct 2020; status: authorised.
02
Drugs
amivantamabcarboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-506033-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506033-29-00.